ImmunoGen Entered into a Multi-Target License and Option Agreement with ImmunoBiochem to Develop Antibody-Drug Conjugates
Shots:
- ImmunoBiochem will receive an up front & will be eligible to receive milestones upon achievement of pre-specified development, regulatory & commercial milestones along with royalties as well as eligible to receive an option exercise fees if it chooses to exercise this option
- ImmunoGen gets an exclusive license to existing Abs (generated by ImmunoBiochem) directed against a specific undisclosed target and will also get an option to select additional targets & Abs to license based on preclinical work undertaken by ImmunoBiochem
- ImmunoGen will lead the future clinical development & commercialization activities along with all R&D associated with that program. The collaboration will combine ImmunoGen's linker-payload technology with ImmunoBiochem's Abs directed against specific targets
Ref: Businesswire| Image: ImmunoGen
Related News:- Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
